PUUSTELLI-GROUP
19.3.2020 09:28:05 CET | Business Wire | Press release
Puustelli has innovated a unique furniture system to eliminate moisture problems in bathroom fittings. The furniture frames feature a structure made of biocomposite by injection moulding. The biocomposite is a mixture of polypropylene and chemical pulp fibre, and is a water-resistant, non-toxic, ecological, modifiable and lasting material. This Finnish product innovation has been developed and is made 100% in Finland. The furniture system, which is suitable for kitchen furniture, has been in production in Puustelli Miinus kitchens since back in 2013. Puustelli was granted a European patent for its invention in 2018.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005234/en/
Water-resistant material
Most bathroom fittings typically have a frame of MDF or particleboard, both of which have poor moisture resistance. The biocomposite frame in Puustelli bathroom fittings can fully withstand water and comes with a 30-year guarantee.
Low-emission concept
Formaldehyde is also present in the panel materials typically used in bathroom fittings. When emitted into the indoor air, formaldehyde is harmful to the health. Even when the panel structure is only slightly damaged, the impact of moisture multiplies the harmful effects. The Puustelli biocomposite frame has a formaldehyde content of exactly 0%. Not only that, the biocomposite is antistatic and does not attract dust.
Ecological solution
Once a frame made from conventional furniture board has absorbed moisture, it can no longer be repaired and must be disposed of and replaced. The Puustelli biocomposite frame on the other hand is a fully reusable and recyclable material. Since it is recyclable, any waste raw material originating in the manufacturing process of the Puustelli biocomposite frame can be efficiently reused.
Puustelli bioframe can be modified
Unlike traditional frame materials, the Puustelli bioframe doesn’t tire of modification or being moved. The frame has precise dimensional accuracy and fittings and materials that affect its appearance can be switched around numerous times if required without the screw fastenings becoming fatigued. The furniture is available for large and small spaces alike. The frames can be finished in various ways depending on the range. Puustelli has also developed from the composite for the frame, a design end panel with a restrained pattern suitable for different styles. Small locators have also been made in the panel in conjunction with injection moulding to make it easy to screw the end panel accurately into the ready-made holes in the frame. The bioframes of the washbasin cupboards have been designed for careful use of space. Plumbing has also been taken into account and if necessary can easily be accessed later. Base cabinets come at a height of 613 mm and widths vary between 200 mm and 1200 mm depending on the model. Since the depth is just 370 mm, they can fit into small spaces.
“The bathroom product development process has been long and at times challenging, but the outcome was well worth all the work. Following our kitchen furniture, a similar bathroom fitting innovation was already anticipated and is now in production,” says Jussi Aine, CEO, Puustelli Group Oy.
Puustelli Group Oy is a Finnish family enterprise and part of the century-old Harjavalta Group, which also includes Kastelli Group Oy and Lapti Group Oy. The Group had a turnover of €491 million in 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
